Imdevimab

Imdevimab_structure.png

Imdevimab is a monoclonal antibody used in combination with casirivimab for the treatment and prevention of COVID-19. It is part of the antibody cocktail known as REGEN-COV, developed by Regeneron Pharmaceuticals. Imdevimab targets the spike protein of the SARS-CoV-2 virus, inhibiting its ability to infect human cells.

Mechanism of Action

Imdevimab is a fully human monoclonal antibody that binds to the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2. By binding to this region, imdevimab blocks the virus from attaching to the ACE2 receptor on human cells, thereby preventing viral entry and subsequent infection. This mechanism is similar to that of other monoclonal antibodies targeting viral proteins, such as those used in the treatment of Ebola virus disease.

Clinical Use

Imdevimab, in combination with casirivimab, received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in patients at high risk of progressing to severe disease. The combination is administered either intravenously or subcutaneously.

Efficacy

Clinical trials have demonstrated that the combination of imdevimab and casirivimab reduces viral load, decreases the risk of hospitalization, and shortens the duration of symptoms in non-hospitalized patients with COVID-19. The efficacy of the treatment is contingent upon early administration, ideally within 10 days of symptom onset.

Safety

The safety profile of imdevimab is generally favorable, with most adverse effects being mild to moderate in severity. Common side effects include infusion-related reactions, such as fever, chills, and headache. Serious hypersensitivity reactions are rare but have been reported.

Development and Approval

Imdevimab was developed by Regeneron Pharmaceuticals using their proprietary VelocImmune technology, which utilizes genetically modified mice to produce fully human antibodies. The development process was expedited due to the urgent need for effective COVID-19 treatments during the pandemic.

Regulatory Status

As of 2023, imdevimab is authorized for emergency use in several countries, including the United States, under specific conditions. The EUA allows for its use in certain populations, such as those with underlying health conditions that increase the risk of severe COVID-19.

Also see

• Casirivimab
• Monoclonal antibody therapy
• COVID-19 pandemic
• SARS-CoV-2
• Spike protein